What does RECIST criteria mean for evaluating Prostate Cancer treatment

Understanding RECIST Criteria in Prostate Cancer Treatment

RECIST is an important framework doctors use to measure whether cancer treatment is working, but it has some specific limitations when applied to prostate cancer. Let me explain what it means and why it matters for your situation.

What RECIST Stands For

RECIST = Response Evaluation Criteria in Solid Tumors

It's a standardized system that uses imaging scans (like CT or MRI) to measure whether tumors are shrinking, staying the same size, or growing after treatment.

How RECIST Works

Doctors measure the size of visible tumors on scans and compare them over time:

• Complete Response (CR): All tumors disappear
• Partial Response (PR): Tumors shrink by at least 30%
• Stable Disease (SD): Tumors don't shrink or grow significantly
• Progressive Disease (PD): Tumors grow by 20% or more

Why RECIST Has Limitations for Prostate Cancer

According to the CancerPatientLab webinar on Bipolar Androgen Therapy for Prostate Cancer featuring Dr. [removed] Antonarakis, RECIST criteria alone can be misleading for prostate cancer patients:

The key challenge: Prostate cancer often spreads to bones, and bone metastases (cancer spread to bones) don't always show up clearly on standard imaging used for RECIST measurements. This means RECIST might not capture the full picture of how well treatment is working.

What Doctors Actually Use for Prostate Cancer

Rather than relying solely on RECIST, your oncology team typically monitors multiple markers together:

1. PSA (Prostate-Specific Antigen) levels - Often the most important marker for prostate cancer response
2. Imaging scans - Including bone scans and PSMA-PET scans (which specifically target prostate cancer cells)
3. Clinical symptoms - How you're feeling and functioning
4. Liquid biopsies - Blood tests that can detect cancer DNA

According to Dr. [removed] webinar, PSA changes are often more reliable than scan changes in the short term. However, he notes an important caveat: "Sometimes PSA will increase but cancer scans show no growth or even regression. Sometimes increased bone metastasis activity appears to occur for about 2-3 months before drastic reductions in activity are seen."

Important Context: The "Bone Scan Flare" Phenomenon

Dr. [removed] describes a critical situation where RECIST-type thinking can be misleading. Some treatments (like Bipolar Androgen Therapy) can cause a temporary worsening on bone scans before improvement occurs—what's called a "bone scan flare." A scan might look worse at 3 months while PSA is actually dropping, indicating the treatment IS working.

Questions to Ask Your Oncologist

To ensure you're being evaluated comprehensively:

1. "What specific markers are you using to assess my treatment response—PSA, scans, or both?"
2. "How often will you be checking my PSA and imaging, and what changes would indicate the treatment is working?"
3. "If my PSA goes up but my scans are stable, how will you interpret that?"
4. "Are you using PSMA-PET scans or standard bone scans, and why?"
5. "What would make you consider switching treatments—PSA levels, scan changes, or symptoms?"

The Bottom Line

RECIST criteria are a useful tool, but for prostate cancer, your doctors should be using a multi-faceted approach that includes PSA trends, imaging findings, and how you're feeling. Don't be surprised if your oncologist emphasizes PSA changes over scan measurements—that's actually the standard approach for prostate cancer monitoring.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.